Expression of bone marrow stromal antigen-2 in primary Sjogren's syndrome and its clinical significance

doi:10.19438/j.cjoms.2018.05.005

Abstract

Abstract: PURPOSE: To analyze bone marrow stromal antigen-2 (BST-2) levels in labial glands, total peripheral blood mononuclear cells (PBMCs) and PBMC subpopulations from primary Sjögren's syndrome (pSS) patients, and explore the role of BST-2 in the pathogenesis of pSS. METHODS: PBMC subsets were positively separated using magnetic microbeads. BST-2 mRNA levels in labial glands, total PBMCs and PBMC subsets of 30 pSS and 30 healthy control (HC) subjects were investigated using real-time PCR (RT-PCR). Distribution of BST-2-positive cells in the labial glands was assessed by immunohistochemistry. Lentivirus transfection in Raji cells were conducted to determine the biologic function of BST-2. SPSS 16.0 software package was used for statistical analysis. Differences between the groups were analyzed using Mann Whitney test, and correlations were assessed using Spearman correlation analysis. RESULTS: BST-2 was increased in pSS labial glands and was positively correlated with VAS value for parotid gland swelling and rheumatoid factor and β2-microglobulin serum levels. BST-2 levels were significantly different between pSS patients with positive and negative expression of anti-SSA antibody. Positive focal infiltrating lymphocytes and adjacent ductal epithelial cells were observed in labial glands from pSS patients, while there were a few scattered positive ductal epithelial cells in controls. BST-2 was up-regulated in peripheral CD19⁺ B cells and labial CD19⁺ B cells from pSS patients. BST-2-overexpressed Raji cells possessed higher proliferative activity and lower apoptotic rate. CONCLUSIONS: BST-2 was aberrantly expressed in B cells of pSS patients, and expression in labial glands was positively correlated with important clinical characteristics. BST-2 might accelerate the progress of pSS by promoting infiltration of B cells.

Key words: Sjögren's syndrome;, BST-2, B cell, CD19, Labial glands

CLC Number:

R781.7

CHEN Chan, ZHENG Ling-yan, SHI Huan, YU Chuang-qi, CAO Ning-ning. Expression of bone marrow stromal antigen-2 in primary Sjogren's syndrome and its clinical significance[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(5): 409-415.

References

[1] Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al.Primary Sjögren syndrome[J]. BMJ, 2012, 344: e3821.
[2] Ice JA, Li H, Adrianto I, et al.Genetics of Sjögren's syndrome in the genome-wide association era[J]. J Autoimmun, 2012, 39(1-2): 57-63.
[3] Neil SJ, Zang T, Bieniasz PD.Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu[J]. Nature, 2008, 451(7177): 425-430.
[4] Van Damme N, Goff D, Katsura C, et al.The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein[J]. Cell Host Microbe, 2008, 3(4): 245-252.
[5] Kupzig S, Korolchuk V, Rollason R, et al.Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology[J]. Traffic, 2003, 4(10): 694-709.
[6] Yi EH, Yoo H, Noh KH, et al.BST-2 is a potential activator of invasion and migration in tamoxifen-resistant breast cancer cells[J]. Biochem Biophys Res Commun, 2013, 435(4): 685-690.
[7] Cai D, Jie C, Zhen L, et al.Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis[J]. BMC Cancer, 2009, 9: 102.
[8] Mahauad-Fernandez WD, Okeoma CM.Cysteine-linked dimerization of BST-2 confers anoikis resistance to breast cancer cells by negating proapoptotic activities to promote tumor cell survival and growth[J]. Cell Death Dis, 2017, 8(3): e2687.
[9] Jeffries MA, Dozmorov M, Tang Y, et al.Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus[J]. Epigenetics, 2011, 6(5): 593-601.
[10] Nexo BA, Hansen B, Nissen KK, et al.Restriction genes for retroviruses influence the risk of multiple sclerosis[J]. PLoS One, 2013, 8(9): e74063.
[11] Shi H, Cao N, Pu Y, et al.Long non-coding RNA expression profile in minor salivary gland of primary Sjögren's syndrome[J]. Arthritis Res Ther, 2016, 18(1): 109.
[12] Vitali C, Bombardieri S, Jonsson R, et al.Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61(6): 554-558.
[13] Sakuma T, Noda T, Urata S, et al.Inhibition of Lassa and Marburg virus production by tetherin[J]. J Virol, 2009, 83(5): 2382-2385.
[14] Tokarev A, Suarez M, Kwan W, et al.Stimulation of NF-κB activity by the HIV restriction factor BST2[J]. J Virol, 2013, 87(4): 2046-2057.
[15] Viswanathan K, Smith MS, Malouli D, et al.BST2/Tetherin enhances entry of human cytomegalovirus[J]. PLoS Pathog, 2011, 7(11): e1002332.
[16] Cao W, Bover L, Cho M, et al.Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction[J]. J Exp Med, 2009, 206(7): 1603-1614.
[17] Kallenberg CG, Vissink A, Kroese FG, et al.What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?[J]. Arthritis Res Ther, 2011, 13(1): 205.
[18] Pertovaara M, Korpela M.Serum beta2 microglobulin correlates with the new ESSDAI in patients with Sjögren's syndrome[J]. Ann Rheum Dis, 2011, 70(12): 2236-2237.
[19] Xie J, Yi Q.Beta2-microglobulin as a potential initiator of inflammatory responses[J]. Trends Immunol, 2003, 24(5): 228-229.
[20] Sumida T, Namekawa T, Maeda T, et al.New T-cell epitope of Ro/SS-A 52 kDa protein in labial salivary glands from patients with Sjögren's syndrome[J]. Lancet, 1996, 348(9042): 1667.
[21] Tan EM.Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology[J]. Adv Immunol, 1989, 44: 93-151.
[22] Gong S, Osei E, Kaplan D, et al.CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia[J]. Int J Clin Exp Pathol, 2015, 8(2): 1613-1621.
[23] Ishikawa J, Kaisho T, Tomizawa H, et al.Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth[J]. Genomics, 1995, 26(3): 527-534.
[24] Kuang CM, Fu X, Hua YJ, et al.BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer[J]. Cell Death Dis, 2017, 8(6): e2874.